Last reviewed · How we verify
Pioglitazone, Rosiglitazone
Pioglitazone and rosiglitazone are thiazolidinediones that activate peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity and reduce blood glucose in type 2 diabetes.
Pioglitazone and rosiglitazone are thiazolidinediones that activate peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity and reduce blood glucose in type 2 diabetes. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Pioglitazone, Rosiglitazone |
|---|---|
| Sponsor | Korea University Anam Hospital |
| Drug class | Thiazolidinedione (PPAR-γ agonist) |
| Target | PPAR-γ (Peroxisome proliferator-activated receptor gamma) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
These drugs bind to PPAR-γ, a nuclear receptor involved in glucose and lipid metabolism, enhancing insulin sensitivity in muscle, adipose tissue, and liver. By reducing insulin resistance, they lower fasting and postprandial glucose levels without directly stimulating insulin secretion. This mechanism makes them effective for glycemic control in type 2 diabetes, though they carry metabolic side effects including weight gain and fluid retention.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Weight gain
- Fluid retention / edema
- Hypoglycemia (when combined with other agents)
- Heart failure exacerbation
- Bone fractures (increased risk)
Key clinical trials
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
- Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh (PHASE4)
- BRL49653C In Type 2 Diabetes -Comparison Study With Pioglitazone And Placebo By Monotherapy- (PHASE3)
- Validation Study of Multiple Probe Compounds for Drug Interaction Evaluation (PHASE1)
- Fracture Risk With Thiazolidinediones
- Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128) (PHASE3)
- Thiazolidinedione Intervention With Vitamin D Evaluation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pioglitazone, Rosiglitazone CI brief — competitive landscape report
- Pioglitazone, Rosiglitazone updates RSS · CI watch RSS
- Korea University Anam Hospital portfolio CI